U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Tay-Sachs disease(TSD)

MedGen UID:
11713
Concept ID:
C0039373
Disease or Syndrome
Synonyms: GM2 gangliosidosis, type 1; HexA deficiency; Hexosaminidase A Deficiency; Hexosaminidase alpha-subunit deficiency (variant B); Sphingolipidosis, Tay-Sachs; TSD
SNOMED CT: Tay-Sachs disease (111385000); Severe hexosaminidase A deficiency (111385000); Hexosaminidase A deficiency (111385000); GM2 gangliosidosis, B, B1 variant (111385000)
Modes of inheritance:
Autosomal recessive inheritance
MedGen UID:
141025
Concept ID:
C0441748
Intellectual Product
Source: Orphanet
A mode of inheritance that is observed for traits related to a gene encoded on one of the autosomes (i.e., the human chromosomes 1-22) in which a trait manifests in individuals with two pathogenic alleles, either homozygotes (two copies of the same mutant allele) or compound heterozygotes (whereby each copy of a gene has a distinct mutant allele).
 
Gene (location): HEXA (15q23)
 
Monarch Initiative: MONDO:0010100
OMIM®: 272800
Orphanet: ORPHA845

Disease characteristics

Excerpted from the GeneReview: HEXA Disorders
HEXA disorders are best considered as a disease continuum based on the amount of residual beta-hexosaminidase A (HEX A) enzyme activity. This, in turn, depends on the molecular characteristics and biological impact of the HEXA pathogenic variants. HEX A is necessary for degradation of GM2 ganglioside; without well-functioning enzymes, GM2 ganglioside builds up in the lysosomes of brain and nerve cells. The classic clinical phenotype is known as Tay-Sachs disease (TSD), characterized by progressive weakness, loss of motor skills beginning between ages three and six months, decreased visual attentiveness, and increased or exaggerated startle response with a cherry-red spot observable on the retina followed by developmental plateau and loss of skills after eight to ten months. Seizures are common by 12 months with further deterioration in the second year of life and death occurring between ages two and three years with some survival to five to seven years. Subacute juvenile TSD is associated with normal developmental milestones until age two years, when the emergence of abnormal gait or dysarthria is noted followed by loss of previously acquired skills and cognitive decline. Spasticity, dysphagia, and seizures are present by the end of the first decade of life, with death within the second decade of life, usually by aspiration. Late-onset TSD presents in older teens or young adults with a slowly progressive spectrum of neurologic symptoms including lower-extremity weakness with muscle atrophy, dysarthria, incoordination, tremor, mild spasticity and/or dystonia, and psychiatric manifestations including acute psychosis. Clinical variability even among affected members of the same family is observed in both the subacute juvenile and the late-onset TSD phenotypes. [from GeneReviews]
Authors:
Camilo Toro  |  Leila Shirvan  |  Cynthia Tifft   view full author information

Additional descriptions

From OMIM
Tay-Sachs disease is an autosomal recessive, progressive neurodegenerative disorder which, in the classic infantile form, is usually fatal by age 2 or 3 years.  http://www.omim.org/entry/272800
From MedlinePlus Genetics
Tay-Sachs disease is a rare, inherited disorder that is characterized by neurological problems caused by  the death of nerve cells (neurons) in the brain and spinal cord (central nervous system).

The most common form of Tay-Sachs disease, known as infantile Tay-Sachs disease, becomes apparent early in life. Infants with this disorder typically develop normally until they are 3 to 6 months old. During this time, their development slows and muscles used for movement weaken. Affected infants stop achieving normal developmental milestones and begin to lose previously acquired skills such as turning over, sitting, and crawling. Infants with this condition develop an exaggerated startle reaction to loud noises. As the disease progresses, children with Tay-Sachs disease experience involuntary muscle twitches(myoclonic jerks), seizures, difficulty swallowing (dysphagia),vision and hearing loss, and intellectual disability. An eye abnormality called a cherry-red spot, which is identified by eye examination, is characteristic of this disorder. Children with infantile  Tay-Sachs disease usually live only into early childhood.

Two other forms of Tay-Sachs disease, known as juvenile and late-onset, are rare. Signs and symptoms of the juvenile form can appear between the ages of 5 years and late adolescence. Features of late-onset Tay-Sachs disease typically appear in adulthood. People with either of these forms of the condition usually have milder and more variable signs and symptoms than those with the infantile form. Characteristic features of juvenile or late-onset Tay-Saches disease include muscle weakness, loss of muscle coordination (ataxia), speech problems, and psychiatric symptoms. These signs and symptoms vary widely among people with late-onset forms of Tay-Sachs disease.  https://medlineplus.gov/genetics/condition/tay-sachs-disease

Clinical features

From HPO
Cherry red spot of the macula
MedGen UID:
786046
Concept ID:
C2216370
Finding
Pallor of the perifoveal macula of the retina with appearance of a small circular reddish choroid shape as seen through the fovea centralis due to relative transparancy of the macula.
Seizure
MedGen UID:
20693
Concept ID:
C0036572
Sign or Symptom
A seizure is an intermittent abnormality of nervous system physiology characterized by a transient occurrence of signs and/or symptoms due to abnormal excessive or synchronous neuronal activity in the brain.
Apathy
MedGen UID:
39083
Concept ID:
C0085632
Mental or Behavioral Dysfunction
Apathy is a quantitative reduction of motivation and the initiation and persistence of goal-directed behavior, where the accompanying emotions, thoughts, and social interactions are also suppressed.
Dementia
MedGen UID:
99229
Concept ID:
C0497327
Mental or Behavioral Dysfunction
A loss of global cognitive ability of sufficient amount to interfere with normal social or occupational function. Dementia represents a loss of previously present cognitive abilities, generally in adults, and can affect memory, thinking, language, judgment, and behavior.
Exaggerated startle response
MedGen UID:
329357
Concept ID:
C1740801
Finding
An exaggerated startle reaction in response to a sudden unexpected visual or acoustic stimulus, or a quick movement near the face.
Psychomotor deterioration
MedGen UID:
373191
Concept ID:
C1836842
Finding
Loss of previously present mental and motor abilities.
Hypertonia
MedGen UID:
10132
Concept ID:
C0026826
Finding
A condition in which there is increased muscle tone so that arms or legs, for example, are stiff and difficult to move.
Hypotonia
MedGen UID:
10133
Concept ID:
C0026827
Finding
Hypotonia is an abnormally low muscle tone (the amount of tension or resistance to movement in a muscle). Even when relaxed, muscles have a continuous and passive partial contraction which provides some resistance to passive stretching. Hypotonia thus manifests as diminished resistance to passive stretching. Hypotonia is not the same as muscle weakness, although the two conditions can co-exist.
Poor head control
MedGen UID:
322809
Concept ID:
C1836038
Finding
Difficulty to maintain correct position of the head while standing or sitting.
Generalized hypotonia
MedGen UID:
346841
Concept ID:
C1858120
Finding
Generalized muscular hypotonia (abnormally low muscle tone).
Aspiration
MedGen UID:
751786
Concept ID:
C2712334
Finding
Inspiration of a foreign object into the airway.
GM2-ganglioside accumulation
MedGen UID:
341335
Concept ID:
C1848920
Finding
Cellular accumulation of GM2 gangliosides.
Pallor
MedGen UID:
10547
Concept ID:
C0030232
Finding
Abnormally pale skin.
Blindness
MedGen UID:
99138
Concept ID:
C0456909
Disease or Syndrome
Blindness is the condition of lacking visual perception defined as a profound reduction in visual perception. On the 6m visual acuity scale, blindness is defined as less than 3/60. On the 20ft visual acuity scale, blindness is defined as less than 20/400. On the decimal visual acuity scale, blindness is defined as less than 0.05. Blindness is typically characterized by a visual field of no greater than 10 degrees in radius around central fixation.

Professional guidelines

PubMed

Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, Chen E, Sparks TN, Reddi HV, Rajkovic A, Dungan JS; ACMG Professional Practice and Guidelines Committee
Genet Med 2021 Oct;23(10):1793-1806. Epub 2021 Jul 20 doi: 10.1038/s41436-021-01203-z. PMID: 34285390Free PMC Article
Zhang J, Chen H, Kornreich R, Yu C
Methods Mol Biol 2019;1885:233-250. doi: 10.1007/978-1-4939-8889-1_16. PMID: 30506202
Norton ME
Curr Opin Obstet Gynecol 2008 Apr;20(2):157-63. doi: 10.1097/GCO.0b013e3282f73230. PMID: 18388816

Curated

American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders

Recent clinical studies

Etiology

Shaimardanova AA, Solovyeva VV, Issa SS, Rizvanov AA
Int J Mol Sci 2023 Feb 11;24(4) doi: 10.3390/ijms24043627. PMID: 36835039Free PMC Article
Gregg AR, Aarabi M, Klugman S, Leach NT, Bashford MT, Goldwaser T, Chen E, Sparks TN, Reddi HV, Rajkovic A, Dungan JS; ACMG Professional Practice and Guidelines Committee
Genet Med 2021 Oct;23(10):1793-1806. Epub 2021 Jul 20 doi: 10.1038/s41436-021-01203-z. PMID: 34285390Free PMC Article
Leal AF, Benincore-Flórez E, Solano-Galarza D, Garzón Jaramillo RG, Echeverri-Peña OY, Suarez DA, Alméciga-Díaz CJ, Espejo-Mojica AJ
Int J Mol Sci 2020 Aug 27;21(17) doi: 10.3390/ijms21176213. PMID: 32867370Free PMC Article
Patterson MC
Handb Clin Neurol 2013;113:1707-8. doi: 10.1016/B978-0-444-59565-2.00039-3. PMID: 23622392
Myerowitz R
Hum Mutat 1997;9(3):195-208. doi: 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7. PMID: 9090523

Diagnosis

Wei J, Wong LC, Boland S
Int J Mol Sci 2023 Dec 21;25(1) doi: 10.3390/ijms25010131. PMID: 38203300Free PMC Article
Zhang J, Chen H, Kornreich R, Yu C
Methods Mol Biol 2019;1885:233-250. doi: 10.1007/978-1-4939-8889-1_16. PMID: 30506202
Barritt AW, Anderson SJ, Leigh PN, Ridha BH
Pract Neurol 2017 Oct;17(5):396-399. Epub 2017 Jul 24 doi: 10.1136/practneurol-2017-001665. PMID: 28739864
Patterson MC
Handb Clin Neurol 2013;113:1707-8. doi: 10.1016/B978-0-444-59565-2.00039-3. PMID: 23622392
Myerowitz R
Hum Mutat 1997;9(3):195-208. doi: 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7. PMID: 9090523

Therapy

Mansouri V, Tavasoli AR, Khodarahmi M, Dakkali MS, Daneshfar S, Ashrafi MR, Heidari M, Hosseinpour S, Sharifianjazi F, Bemanalizadeh M
Eur J Neurol 2023 Sep;30(9):2919-2945. Epub 2023 Jun 8 doi: 10.1111/ene.15871. PMID: 37209042
Leal AF, Benincore-Flórez E, Solano-Galarza D, Garzón Jaramillo RG, Echeverri-Peña OY, Suarez DA, Alméciga-Díaz CJ, Espejo-Mojica AJ
Int J Mol Sci 2020 Aug 27;21(17) doi: 10.3390/ijms21176213. PMID: 32867370Free PMC Article
Hussein N, Weng SF, Kai J, Kleijnen J, Qureshi N
Cochrane Database Syst Rev 2018 Mar 14;3(3):CD010849. doi: 10.1002/14651858.CD010849.pub3. PMID: 29537064Free PMC Article
Bell CJ, Dinwiddie DL, Miller NA, Hateley SL, Ganusova EE, Mudge J, Langley RJ, Zhang L, Lee CC, Schilkey FD, Sheth V, Woodward JE, Peckham HE, Schroth GP, Kim RW, Kingsmore SF
Sci Transl Med 2011 Jan 12;3(65):65ra4. doi: 10.1126/scitranslmed.3001756. PMID: 21228398Free PMC Article
Janz NK, Becker MH
Health Educ Q 1984 Spring;11(1):1-47. doi: 10.1177/109019818401100101. PMID: 6392204

Prognosis

Wei J, Wong LC, Boland S
Int J Mol Sci 2023 Dec 21;25(1) doi: 10.3390/ijms25010131. PMID: 38203300Free PMC Article
Blondel A, Kraoua I, Marcelino C, Khrouf W, Schlemmer D, Ganne B, Caillaud C, Fernández-Eulate G, Turki IBY, Dauriat B, Bonnefont-Rousselot D, Nadjar Y, Lamari F
Mol Genet Metab 2023 Feb;138(2):106983. Epub 2022 Dec 26 doi: 10.1016/j.ymgme.2022.106983. PMID: 36709536
Cachon-Gonzalez MB, Zaccariotto E, Cox TM
Curr Gene Ther 2018;18(2):68-89. doi: 10.2174/1566523218666180404162622. PMID: 29618308Free PMC Article
Lew RM, Burnett L, Proos AL, Barlow-Stewart K, Delatycki MB, Bankier A, Aizenberg H, Field MJ, Berman Y, Fleischer R, Fietz M
J Paediatr Child Health 2015 Mar;51(3):271-9. Epub 2014 Jun 13 doi: 10.1111/jpc.12632. PMID: 24923490
Myerowitz R
Hum Mutat 1997;9(3):195-208. doi: 10.1002/(SICI)1098-1004(1997)9:3<195::AID-HUMU1>3.0.CO;2-7. PMID: 9090523

Clinical prediction guides

Wei J, Wong LC, Boland S
Int J Mol Sci 2023 Dec 21;25(1) doi: 10.3390/ijms25010131. PMID: 38203300Free PMC Article
Mansouri V, Tavasoli AR, Khodarahmi M, Dakkali MS, Daneshfar S, Ashrafi MR, Heidari M, Hosseinpour S, Sharifianjazi F, Bemanalizadeh M
Eur J Neurol 2023 Sep;30(9):2919-2945. Epub 2023 Jun 8 doi: 10.1111/ene.15871. PMID: 37209042
Han ST, Hirt A, Nicoli ER, Kono M, Toro C, Proia RL, Tifft CJ
J Inherit Metab Dis 2023 Jul;46(4):687-694. Epub 2023 Feb 5 doi: 10.1002/jimd.12596. PMID: 36700853Free PMC Article
Black SH
Curr Opin Pediatr 1994 Dec;6(6):712-6. doi: 10.1097/00008480-199412000-00018. PMID: 7849820
Mahuran DJ, Triggs-Raine BL, Feigenbaum AJ, Gravel RA
Clin Biochem 1990 Oct;23(5):409-15. doi: 10.1016/0009-9120(90)90153-l. PMID: 2147596

Recent systematic reviews

Mansouri V, Tavasoli AR, Khodarahmi M, Dakkali MS, Daneshfar S, Ashrafi MR, Heidari M, Hosseinpour S, Sharifianjazi F, Bemanalizadeh M
Eur J Neurol 2023 Sep;30(9):2919-2945. Epub 2023 Jun 8 doi: 10.1111/ene.15871. PMID: 37209042
Hussein N, Henneman L, Kai J, Qureshi N
Cochrane Database Syst Rev 2021 Oct 11;10(10):CD010849. doi: 10.1002/14651858.CD010849.pub4. PMID: 34634131Free PMC Article
Hussein N, Weng SF, Kai J, Kleijnen J, Qureshi N
Cochrane Database Syst Rev 2018 Mar 14;3(3):CD010849. doi: 10.1002/14651858.CD010849.pub3. PMID: 29537064Free PMC Article
Hussein N, Weng SF, Kai J, Kleijnen J, Qureshi N
Cochrane Database Syst Rev 2015 Aug 12;2015(8):CD010849. doi: 10.1002/14651858.CD010849.pub2. PMID: 26264938Free PMC Article
Lew RM, Burnett L, Proos AL, Barlow-Stewart K, Delatycki MB, Bankier A, Aizenberg H, Field MJ, Berman Y, Fleischer R, Fietz M
J Paediatr Child Health 2015 Mar;51(3):271-9. Epub 2014 Jun 13 doi: 10.1111/jpc.12632. PMID: 24923490

Supplemental Content

Table of contents

    Clinical resources

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Curated

    • ACMG ACT, 2011
      American College of Medical Genetics ACT Sheet, Carrier Screening ACT Sheet Ashkenazi Jewish Genetic Disorders

    Recent activity

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...